Pharma: Clinic Roundup

May 2013
BioWorld Today;5/13/2013, Vol. 24 Issue 91, p9
The article reports that Eli Lilly and Co. of Indianapolis, Indiana will stop development of enzastaurin, a monotherapy in preventing relapse in patients with diffuse large B-cell lymphoma, based on findings of Phase III PRELUDE study of enzastaurin.


Related Articles

  • Pfizer and Lilly shoulder novel pain-drug risks. Sinha, Gunjan // Nature Biotechnology;Jan2014, Vol. 32 Issue 1, p9 

    The article reports on the deal between pharmaceutical companies New York-based Pfizer and Eli Lilly & Co. in Indianapolis, Indiana in October 2013 for the development of the former's anti-nerve growth factor drug known as tanezumab.

  • ELI LILLY & COMPANY (NYSE: LLY).  // Acquisdata Company SnapShot: Eli Lilly & Company;10/31/2016, Issue 1162, preceding p1 

    A company profile of drug developer Eli Lilly & Co. is presented, with topics on the company's latest financial announcement as of October 31, 2016, the condition of the industry, and its key competitors.

  • Lilly to double staff researching combo drugs. Wall, J. K. // Indianapolis Business Journal;7/11/2011, Vol. 32 Issue 19, p20A 

    The article reports on the initiative of Eli Lilly and Co. to double the size of its staff that researches on combination drugs, which will aid in the development of a 2-in-1 biotech drugs called multi-specific therapeutics.

  • COMPANY SPOTLIGHT - Eli Lilly and Company.  // PharmaWatch: CNS;Feb2008, Vol. 7 Issue 2, p18 

    The article presents a corporate profile of pharmaceutical firm Eli Lilly & Co. The company is collaborating to discover and develop drugs for the treatment of metabolic diseases, central nervous system disorders and other diseases. Eli Lilly & Co. has a strong diabetes portfolio. It also...

  • In spite of criticism, Lilly saves lives. Schenck, Steven J. // Indianapolis Business Journal;3/30/2009, Vol. 30 Issue 4, p11A 

    The author shares his views on the success of Indianapolis, Indiana-based drug company Eli Lilly & Co. in introducing the trial drug Enzastaurin, which has saved the life of his wife. He narrates how his wife suffering from glioblastoma was cured by a clinical trial using the drug. The author...

  • Lilly gets ready for life after Prozac.  // Indianapolis Business Journal;7/2/2001, Vol. 22 Issue 16, p3A 

    Reports that pharmaceutical company Eli Lilly and Co. wants to take full advantage of drugs it launched in the last half of the 1990s to replace an anticipated drop in Prozac revenue. Plan to continue developing a pipeline of products; Maintenance of leadership in developing drugs to treat...

  • News Update.  // Applied Clinical Trials;Sep2002, Vol. 11 Issue 9, p16 

    Reports on developments in drug development as of September 2002. U.S. Food and Drug Administration's approval for Eli Lilly and Co.'s intermittent dosing of Sarafem for the treatment of premenstrual dysphoric disorder; Clinical trials in progress.

  • The path to solanezumab.  // Indianapolis Business Journal;8/13/2012, Vol. 33 Issue 24, p28 

    The article outlines the search of treatment for Alzheimer's disease since 1906 towards the development of solanezumab from Eli Lilly and Co. in 1988 and its improvement until 2012.

  • Deciphera's B-Raf Inhibitor Program Lands Deal with Lilly. Boggs, Jennifer // BioWorld Today;10/6/2008, Vol. 19 Issue 194, p1 

    This article reports on a drug development deal signed by Deciphera Pharmaceuticals LLC with Eli Lilly and Co. in 2008. Deciphera licenses rights to four preclinical B-Raf kinase inhibitors to Eli Lilly for the development of oncology drugs. Daniel Flynn, president and chief executive officer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics